You searched for Rare Diseases - Page 47 of 50

- 19 July 2018

Ipsen and BioLabs to open new Innovation Center in Cambridge (U.S.) to foster development of new therapies for patients

Ipsen Innovation Center – BioLabs to be located in Ipsen’s new and third global hub in the heart of Cambridge, Massachusetts...

- 04 July 2018

Ipsen announces CELESTIAL phase 3 pivotal trial results in the New England Journal of Medicine

...

- 18 January 2019

Patients living with spasticity want long-lasting symptom relief

Attachment...

- 12 October 2018

Ipsen to present new data from its oncology portfolio at the 2018 European Society for Medical Oncology (ESMO) congress

Paris (France), 12 October 2018 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that cabozantinib (Cabometyx®), irinotecan liposome injection (Onivyde®), lanreotide (Somatuline®) and the combination of lanreotide and telotristat (Xermelo®) a...

- 17 May 2018

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma

...

- 23 March 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma

...

- 07 February 2018

Ipsen announces eight oral presentations from its Neurosciences portfolio at the 10th World Congress for Neurorehabilitation (WCNR)

...

- 21 February 2018

Arix Bioscience and Ipsen sign a strategic agreement to develop and commercialise innovative therapies

...

- 16 January 2018

Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma

...